Article Text

Download PDFPDF

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors
Free
  1. Anissa Roger1,
  2. Matthieu Groh2,
  3. Gwenael Lorillon3,
  4. Claire Le Pendu2,
  5. Jeremy Maillet4,
  6. Dimitri Arangalage5,6,7,
  7. Abdellatif Tazi3,6,8,
  8. Celeste Lebbe1,6,9,
  9. Barouyr Baroudjian1,
  10. Julie Delyon1,6,9
  11. the PATIO group
  1. 1 Department of Dermatology, AP-HP Hôpital Saint Louis, Paris, France
  2. 2 Department of Internal Medicine, AP-HP Hôpital Saint Louis, Paris, France
  3. 3 Department of Pneumology, AP-HP Hôpital Saint Louis, Paris, France
  4. 4 Department of Rheumatology, AP-HP Hôpital Lariboisière, Paris, France
  5. 5 Department of Cardiology, AP-HP Hôpital Bichat, Paris, France
  6. 6 Université Paris Diderot, Paris, France
  7. 7 INSERM U1148, Hôpital Bichat, Paris, France
  8. 8 U1153 CRESS, Equipe de Recherche en Biostatistiques et Epidémiologie Clinique, Paris, France
  9. 9 INSERM U976, Hôpital Saint Louis, Paris, France
  1. Correspondence to Dr Julie Delyon, Department of Dermatology, AP-HP Hôpital Saint Louis, Paris Île-de-France, 75010 Paris, France; julie.delyon{at}aphp.fr

Statistics from Altmetric.com

We read with great interest the articles by Kostine et al 1 (and subsequent correspondence by Arnaud et al 2) and by Belkhir et al. 3 The prognosis of various cancer types has dramatically improved since the advent of immune checkpoint inhibitors (ICIs). Yet, ICI therapy is associated with frequent and potentially organ or life-threatening immune-related adverse events (irAEs), generally mimicking autoimmune or inflammatory conditions.4 Rheumatic disorders have been reported in this setting, mainly rheumatoid arthritis, polymyalgia rheumatica and systemic lupus erythematosus.1–3 Vasculitis seems to occur more seldom, with predominantly medium-vessel to large-vessel involvement.5 Here, we report on a patient with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) following treatment with ICI for a stage IV melanoma.

A 34-year-old non-smoking female patient with stage IV melanoma was treated with ipilimumab (a monoclonal antibody targeting the cytotoxic T–lymphocyte associated antigen …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles